Drug Kinetics and Continuous Arteriovenous Hemofiltration

  • T. Golper
Part of the Developments in Nephrology book series (DINE, volume 13)


Since Kramer’s initial description of the procedure he called continuous arteriovenous hemofiltration (CAVH) (1), its role in the management of acute renal failure has been considerably expanded (2–4). Because most patients undergoing CAVH are critically ill, optimal management of concurrent medications is a necessity. Only recently has drug handling during CAVH been studied in any detail (4–8). It is the purpose of this chapter to review the factors related to drug handling during CAVH, to establish uniform terminology and methodology for drug data collection, to summarize the available data concerning specific drugs, and to recommend an approach to drug administration in patients undergoing CAVH.


Unbind Fraction Drug Kinetic Drug Removal Plasma Water Ultrafiltration Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kramer P, Wigger W. Rieger J, et al: Arteriovenous hemofiltration: a new and simple method for treatment of overhydrated patients resistant to diuretics. Klin Wochenschr 55:1121–2, 1977.PubMedCrossRefGoogle Scholar
  2. 2.
    Golper TA: Continuous arteriovenous hemofiltration in acute renal failure. Am J Kid Dis 1985 (In press).Google Scholar
  3. 3.
    Kaplan AA, Longnecker RE, Folkert VW: Continuous arteriovenous hemofiltration. Ann Intern Med 100:358–367, 1984.PubMedGoogle Scholar
  4. 4.
    Paganini EP, O’Hara P, Nakamoto S: Slow continuous Ultrafiltration in hemodialysis resistant oliguric acute renal failure patients. Trans Am Soc Artif Intern Organs 30:173–177, 1984.PubMedGoogle Scholar
  5. 5.
    Kaplan AA, Longnecker RE, Folkert VW: Continuous hemofiltration: in response (Letters). Ann Intern Med 101:145–146, 1984.Google Scholar
  6. 6.
    Ossenkopple GJ, Van der Muellen J, Bronsveld W, et al: Continuous arteriovenous hemofiltration as an adjunctive therapy for septic shock. Crit Care Med 13:102–104, 1985.CrossRefGoogle Scholar
  7. 7.
    Golper TA, Pulliam J, Bennett WM: Removal of therapeutic drugs by continuous arteriovenous hemofiltration. Arch Intern Med 145:1651–1652, 1985.PubMedCrossRefGoogle Scholar
  8. 8.
    Golper TA, Wedel SK, Kaplan AA, Saad A-M, Donta ST, Paganini EP: Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Intern J Artif Organs 1985 (In press).Google Scholar
  9. 9.
    Colton CK, Henderson LW, Ford CA, et al: Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow fiber blood ultrafilter. J Lab Clin Med 85:355–371, 1975.PubMedGoogle Scholar
  10. 10.
    Leypoldt JK, Frigon RP, Henderson LW: Dextran sieving coefficients of hemofilter membranes. Trans Am Soc Artif Intern Organs 29:678–683, 1983.PubMedGoogle Scholar
  11. 11.
    Frigon RP, Leypoldt JK, Alford MF, et al: Hemofilter solute sieving is not governed by dynamically polarized protein. Ibid. 486–490, 1984.Google Scholar
  12. 12.
    Golper TA, Saad A-M: Gentamicin and phenytoin in vitro sieving characteristics through polysulfone hemofilters: effect of flow rate, drug concentration, and solvent hemofilters: effect of flow rate, drug concentration, and solvent systems (submitted for review).Google Scholar
  13. 13.
    Reidenberg MM, Affrime M: Influence of disease on binding of drugs to plasma protein. Ann NY Acad Sci 226:115–126, 1973.PubMedCrossRefGoogle Scholar
  14. 14.
    Dayton PG, Israili ZH, Perel JM: Influence of binding on drug metabolism and distribution. Ibid. 226:172–194, 1973.Google Scholar
  15. 15.
    Anton AH: Increasing activity of sulfonamides with displacing agents. Ibid. 226:273–292, 1973.Google Scholar
  16. 16.
    Reidenberg MM: The binding of drugs to plasma protein and the interpretation of measurements of plasma concentration of drugs in patients with poor renal function. Am J Med 62:460–470, 1977.Google Scholar
  17. 17.
    Tillement JP, Lhoste F, Fiudicelli TF: Diseases and drug protein binding. Clin Pharmacokin 3:144–154, 1978.CrossRefGoogle Scholar
  18. 18.
    McNamara PJ, Lalka D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98:740, 1981.Google Scholar
  19. 19.
    Gulyassy PF, Depner TA: Impaired binding of drugs and endogenous ligands in renal disease. Am J Kid Dis 2:578–601, 1983.PubMedGoogle Scholar
  20. 20.
    Keller F, Wilms H, Schulte G, et al: Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodi-alysis. Clin Nephrol 19:201–205, 1983.PubMedGoogle Scholar
  21. 21.
    Suh B, Craig WA, England AC, et al: Effect of the free fatty acids on protein binding of antimicrobial agents. J Infect Dis 143:609–616.Google Scholar
  22. 22.
    Kraft D, Lode H: Elimination of ampicillin and genta-micin by hemofiltration. Klin Wochenschr 57:195–196, 1979.PubMedCrossRefGoogle Scholar
  23. 23.
    Klein E, Holland FF, Eberle K: Rejection of solutes by hemofiltration membranes. ASAIO J 1:15–23, 1978.Google Scholar
  24. 24.
    Rockel A, Gilge U, Liewald A, et al: Elimination of low molecular weight proteins during hemofiltration. Artif Organs 6:307–311, 1982.PubMedCrossRefGoogle Scholar
  25. 25.
    Michaels AS: Analysis and prediction of sieving curves for ultrafiltration membranes: a universal correlation? Separation Sci and Tech 15:1305–1322, 1980.CrossRefGoogle Scholar
  26. 26.
    Feldhoff P, Tunham T, Klein E: Effect of plasma proteins on the sieving spectra of hemofilters. Artif Organs 8:186–192, 1984.PubMedCrossRefGoogle Scholar
  27. 27.
    Jaffrin MY, Vantard G, Granger A: A concentration polarization model of hemofiltration with highly permeable membranes. ASAIO J 2:73–85, 1985.Google Scholar
  28. 28.
    Dodd NJ, O’Donovan RM, Bennett-Jones DN: Arteriovenous haemofiltration: a recent advance in the management of renal failure. Br Med J 287:1008–1010, 1983.CrossRefGoogle Scholar
  29. 29.
    Pauls A, Grigoleit H-G, Von Herrath D, Schaefer K: Comparison of drug elimination by current methods of blood purification. Blood Purification 2:14–22, 1984.CrossRefGoogle Scholar
  30. 30.
    Zarowitz BJM, Anandan JV, Jayashankar J, et al: Ultra-filtration clearance of aminoglycoside antibiotics. Drug Intell Clin Pharm 19:459, 1985.Google Scholar
  31. 31.
    Lauer A, Saccaggi A, Ronco C, et al: Continuous arteriovenous hemofiltration in the critically ill patient. Ann Intern Med 99:455–460, 1983.PubMedGoogle Scholar
  32. 32.
    Bennett WM, Aronoff GR, Morrison G, et al: Drug prescribing in renal failure: dosing guidelines for adults. Am J Kid Dis 3:155–193, 1983.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing 1986

Authors and Affiliations

  • T. Golper
    • 1
  1. 1.Oregon Health Sciences UniversityPortlandUSA

Personalised recommendations